Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis
- Sponsor
- Tanja Todberg, MD
- Study ID
- NCT03576287
- Phase
- PHASE1/PHASE2
- Status
- Unknown
Conditions
- Prurigo Nodularis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Apremilast Oral Product — DRUGApremilast
Study Details
This study will evaluate the anti-pruritic effect of apremilast in patients with known PN.
Key Dates
- First listed
- Jul 3, 2018
- Start date
- Jul 1, 2017
- Status verified
- Jul 2018
- Primary completion
- Dec 1, 2019
- Completion
- Dec 1, 2019
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: apremilastapremilast standard doses
Primary Outcome Measure
1. Reduction in mean absolute VAS-pruritus score after 12 weeks treatment with apremilast compared to mean VAS-pruritus score before treatment with apremilast [ Time Frame: 12 weeks ]
Related Studies
- A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo NodularisPHASE3 · Recruiting · Sanofi · Palo Alto, California
- Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in AdultsRecruiting · Galderma R&D · Birmingham, Alabama